Institution identification

PURI

https://redirect.ema.europa.eu/resource/3331384

Institution ID

3331384

Institution full name and acronym

Center for International Blood and Marrow Transplant Research (CIBMTR)

ENCePP partner

No
Institution details
Experience with collecting data directly from individual patients or respondents:
No
Interest in carrying out research that is funded by pharmaceutical companies:
No

Studies conducted by the institution

A Non-Interventional Post-Authorisation Safety Study (PASS) of Inotuzumab Ozogamicin to Characterize Complications Post-Hematopoietic Stem Cell Transplantation (HSCT) Following Inotuzumab Ozogamicin Treatment in Adult and Pediatric Patients with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL).
A Non-Interventional Post-Authorisation Safety Study to Characterize Toxicity following Gemtuzumab Ozogamicin Treatment and Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia.
Long-term registry-based study of patients with transfusion-dependent β-thalassemia (TDT) or sickle cell disease (SCD) treated with exagamglogene autotemcel (exa-cel)
Non-interventional, post-authorization safety study (PASS) of patients treated with commercially available liso-cel (lisocabtagene maraleucel) for large B-cell lymphomas (JCAR017-BCM-005)
Post-authorisation safety study of allogeneic haematopoietic cell transplantation in patients treated with mogamulizumab